LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process

Stock News

01/07

LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1153150074"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153150074\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153150074?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153150074","market":"other","top_or_hot":-1,"title":"LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process","media":"Stock News","content":"<p>LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA (01513): Laikangqita Monoclonal Antibody Injection Included in Priority Review and Approval Process\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-07 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1153150074","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153150074","pubTimestamp":1767782761,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药","BK1191":"制药"},"translate_title":"丽珠医药(01513)：莱康奇他单抗注射液纳入优先审评审批程序","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"LIVZON PHARMA (01513) announced that Laikangqita Monoclonal Antibody Injection, a product jointly developed by its controlling subsidiary, Zhuhai Livzon Mabpharm Inc., and Beijing Xinkanghe Biopharmaceutical Technology Co., Ltd., was included in the draft priority review variety list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on December 26, 2025. Following the expiration of the publicity period and according to information published on the CDE website, the product has now been formally included in the priority review variety list, officially entering the priority review and approval process for drug marketing authorization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}